Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia-Reference-Cited by-同舟云学术

Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia

Published:2017-03 Issue:3 Volume:25 Page:816-825
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Flugelman Moshe Y.,Halak Moshe,Yoffe Boris,Schneiderman Jacob,Rubinstein Chen,Bloom Allan-Isaac,Weinmann Eran,Goldin Ilya,Ginzburg Victor,Mayzler Olga,Hoffman Aaron,Koren Belly,Gershtein Diana,Inbar Michal,Hutoran Marina,Tsaba Adili

Funder

VESSL Therapeutics

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference38 articles.

1. Critical limb ischemia;Varu;J. Vasc. Surg.,2010

3. The natural history of untreated severe or critical limb ischemia;Abu Dabrh;J. Vasc. Surg.,2015

4. Improved amputation-free survival in unreconstructable critical limb ischemia and its implications for clinical trial design and quality measurement;Benoit;J. Vasc. Surg.,2012

5. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization;Marston;J. Vasc. Surg.,2006

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination stem cell therapy using dental pulp stem cells and human umbilical vein endothelial cells for critical hindlimb ischemia;BMB Reports;2022-07-31

2. Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia;Cochrane Database of Systematic Reviews;2022-07-08

3. Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes;International Journal of Nanomedicine;2022-06

4. Characteristics and Outcomes of Clinical Trials on Gene Therapy in Noncongenital Cardiovascular Diseases: Cross-sectional Study of Three Clinical Trial Registries;JMIR Formative Research;2022-04-21

5. Therapeutic angiogenesis-based strategy for peripheral artery disease;Theranostics;2022